Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EDNRA | P25101 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5762013 | 0.98 | EDNRA (0.33) | EDNRAKDM4EALDH1A1ALOX15HSD17B10 | |
| SCHEMBL5762009 | 0.96 | EDNRA (0.33) | EDNRA | |
| SCHEMBL19782813 | 0.79 | CA12 (0.35) | KDM4EALDH1A1ALOX15HSD17B10CYP19A1 | |
| SCHEMBL1751661 | 0.78 | KMT2A (0.39) | ALDH1A1ALOX15HSD17B10 | |
| SCHEMBL567737 | 0.75 | CYP19A1 (0.33) | CYP19A1 | |
| SCHEMBL2067485 | 0.73 | PIK3C3 (0.45) | EDNRAHSD17B10CYP19A1 | |
| SCHEMBL3132631 | 0.73 | KDM4E (0.43) | KDM4EALDH1A1ALOX15HSD17B10 | |
| SCHEMBL629463 | 0.72 | ALDH1A1 (0.48) | EDNRAKDM4EALDH1A1ALOX15HSD17B10 | |
| SCHEMBL16914055 | 0.71 | KMT2A (0.44) | KDM4EALDH1A1HSD17B10CYP19A1 | |
| SCHEMBL28940994 | 0.71 | KMT2A (0.35) | KDM4EALDH1A1ALOX15HSD17B10MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12060347-B2 | Bicyclic heteroaryl substituted compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-08-13 | — | — | US | disclosed |
| CN-115916777-B | ATX inhibitor and preparation method and application thereof | 苏州爱科百发生物医药技术有限公司 | 2024-07-12 | — | — | CN | disclosed |
| US-20230295159-A1 | ATX INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | SUZHOU ARK BIOPHARMACEUTICAL CO., LTD. (CN) | 2023-09-21 | — | — | US | disclosed |
| US-20230295159-A1 | ATX INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | SUZHOU ARK BIOPHARMACEUTICAL CO., LTD. (CN) | 2023-09-21 | — | — | US | disclosed |
| US-20230295159-A1 | ATX INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | SUZHOU ARK BIOPHARMACEUTICAL CO., LTD. (CN) | 2023-09-21 | — | — | US | disclosed |
| EP-4180430-A1 | ATX INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Suzhou Ark Biopharmaceutical Co., Ltd (CN) | 2023-05-17 | — | — | EP | disclosed |
| EP-4180430-A1 | ATX INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Suzhou Ark Biopharmaceutical Co., Ltd (CN) | 2023-05-17 | — | — | EP | disclosed |
| CN-115916777-A | ATX inhibitor and preparation method and application thereof | 苏州爱科百发生物医药技术有限公司 | 2023-04-04 | — | — | CN | disclosed |
| CN-109689647-B | Bicyclic heteroaryl substituted compounds | 百时美施贵宝公司 | 2023-01-20 | — | — | CN | disclosed |
| WO-2022007882-A1 | ATX INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 苏州爱科百发生物医药技术有限公司 | 2022-01-13 | — | — | WO | disclosed |
| US-20210163465-A1 | BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2021-06-03 | — | — | US | disclosed |
| US-20210163465-A1 | BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2021-06-03 | — | — | US | disclosed |
| EP-3484878-B1 | BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2020-08-19 | — | — | EP | disclosed |
| US-20190292176-A1 | BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS | BISTOL MYERS SQUIBB COMPANY (US) | 2019-09-26 | — | — | US | disclosed |
| US-20190292176-A1 | BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS | BISTOL MYERS SQUIBB COMPANY (US) | 2019-09-26 | — | — | US | disclosed |
| WO-2018013774-A1 | BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-01-18 | — | — | WO | disclosed |
| EP-1611091-B1 | Substituted phenylalkanoic acid derivatives and their use for respiratory disease treatment | ASTRAZENECA AB (SE) | 2014-10-29 | — | — | EP | disclosed |
| US-8158820-B2 | Compounds | ASTRAZENECA AB (SE) | 2012-04-17 | — | — | US | disclosed |
| US-20110166117-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2011-07-07 | — | — | US | disclosed |
| US-20060264435-A1 | Novel compounds | ASTRAZENECA AB (SE) | 2006-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12060347-B2 | Bicyclic heteroaryl substituted compounds | F2, F2RL3, F12 | EDNRA 502/4885KDM4E 2420/4885ALDH1A1 1598/4885 |
| US-20110166117-A1 | Novel Compounds | ADRA2C, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HCAR2 | EDNRA 167/4885KDM4E 1696/4885ALDH1A1 284/4885 |
| US-20190292176-A1 | BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS | F2, F2RL3, PF4 | EDNRA 920/4885KDM4E 1865/4885ALDH1A1 1618/4885 |
| US-20230295159-A1 | ATX INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | ATXN10, GCG, ATXN2L | EDNRA 4051/4885KDM4E 1181/4885ALDH1A1 2764/4885 |
| US-20060264435-A1 | Novel compounds | ADRA2C, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HCAR2 | EDNRA 167/4885KDM4E 1696/4885ALDH1A1 284/4885 |
| US-20210163465-A1 | BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS | F2, F2RL3, F12 | EDNRA 502/4885KDM4E 2420/4885ALDH1A1 1598/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.